Abstract. Solamargine, an active ingredient of Solanum nigrum, has been previously revealed to inhibit the proliferation of cancer cells. However, the effect of solamargine on human cholangiocarcinoma cells and the underlying molecular mechanism remain unknown. In the present study, the molecular mechanism underlying the anti-cancer effect of solamargine was assessed in human cholangiocarcinoma QBC939 cells. The results of the present study revealed that solamargine inhibited the viability of QBC939 cells in a dose-dependent manner. Furthermore, solamargine significantly induced the apoptosis of QBC939 cells and altered the mitochondrial membrane potential of cells. Quantitative polymerase chain reaction analysis revealed that solamargine decreased the mRNA level of B-cell lymphoma-2 (Bcl-2), Bcl-extra-large and X-linked inhibitor of apoptosis protein but increased the mRNA level of Bcl-2-associated X protein (Bax). In addition, western blot analysis demonstrated that solamargine inhibited the protein expression of Bcl-2 and poly ADP ribose polymerase (PARP), and promoted the protein expression of Bax, cleaved PARP, caspase 3, cleaved caspase 3 and caspase 7. Therefore, the results of the present study revealed that solamargine may induce apoptosis via the mitochondrial pathway and alter the level of apoptosis-associated proteins in human cholangiocarcinoma QBC939 cells. This in vitro study demonstrated that solamargine may be an effective chemotherapeutic agent against cholangiocarcinoma in clinical practice.
Introduction
Cholangiocarcinoma is a common primary biliary malignancy that originates from bile duct epithelial cells and has presented difficulties in diagnosis and treatment (1) . Cholangiocarcinoma, including intrahepatic, perihilar, and distal cholangiocarcinoma, accounts for ~10-15% of total hepatobiliary malignancies (2) . The incidence of cholangiocarcinoma increased from 1832 cases in 2010 to 1964 cases in 2013 in England, and the majority of cholangiocarcinoma patients are >60 years old (3) . Early diagnosis, operative treatment and chemotherapy for cholangiocarcinoma remain ineffective at treating cholangiocarcinoma (4) . Cancer recurrence and metastasis have remained as the important mortality factors for patients with cholangiocarcinoma (5); therefore, the identification of an effective approach to treat human cholangiocarcinoma is required.
Solamargine is an alkaloid that is primarily derived from the Solanum nigrum plant. S. nigrum may exhibit heat-clearing and detoxifying effects, according to the theory of traditional Chinese medicine (6) . Solamargine is an effective active ingredient of S. nigrum that may inhibit the proliferation and induce the apoptosis of multiple types of cancer cell, particularly human hepatocellular carcinoma cells (7) (8) (9) (10) . In addition, solamargine may enhance the susceptibility of human lung cancer and breast cancer to chemotherapeutic drugs (11) (12) (13) . However, the effect of solamargine on human cholangiocarcinoma QBC939 cells and the underlying molecular mechanism remain unknown.
Apoptosis serves an important function in tumor formation and metastasis and is typically repressed in the tumor microenvironment (14, 15) . Therefore, increasing the apoptosis induced by drugs is an effective method to inhibit cancer (16) . In the present study, the effect of solamargine on the viability of cholangiocarcinoma QBC939 cells and associated molecular mechanisms was investigated and Flow cytometry for detecting apoptosis. QBC939 cells, in the period of logarithmic phase, were seeded in 6-well plates (3x10 5 cells/well, in 2 ml RPMI-1640 medium) and cultured overnight at 37˚C in an atmosphere containing 5% CO 2 . Cells were allowed to culture to 70% confluence/well and were treated with solamargine at the indicated concentration (0, 2, 4, 6, 8 and 10 µM) for 24 h at 37˚C. Cells were digested using 0.25% Trypsin-EDTA at 37˚C, washed with PBS and resuspended in 100 µl 1X Binding Buffer (included in the Annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit). Cells in each group (0, 2, 4, 6, 8 and 10 µM) were stained with 5 µl propidium iodide (PI) and 5 µl Annexin V-FITC, according to the Annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit (BD Biosciences, Franklin Lakes, NJ, USA) protocol and incubated for 15 min at room temperature in the dark. An aliquot of 400 µl 1X Binding Buffer was added and the apoptosis of QBC939 cells was detected by Guava easyCyte 6-2L flow cytometer (Merck KGaA, Darmstadt, Germany) and analyzed by the GuavaSoft software (version 2.7; Merck KGaA, Darmstadt, Germany).
Detecting the mitochondrial membrane potential by JC-1 staining buffer. QBC939 cells in the mid-log phase were seeded in 12-well plates (2x10 5 cells/well in 1 ml RPMI 1640 medium) and cultured overnight at 37˚C. Cells were treated with solamargine at 2, 4, 6, 8 and 10 µM for 24 h at 37˚C. The treated cells were washed with PBS two times and digested with 0.25% Trypsin-EDTA. Carbonyl cyanide 3-chlorophenylhydrazone (from the mitochondrial membrane potential assay kit) was added into the positive control well and incubated at 37˚C for 20 min. A total of 1 ml JC-1 staining buffer was added to the wells and incubated for 20 min at 37˚C in the dark. The supernatant was removed at 600 x g for 3 min at room temperature. Cells were washed with JC-1 washing buffer (1X) two times and then suspended in washing buffer. Flow cytometry was conducted to detect JC-1 fluorescence and analyze the change in mitochondrial membrane potential (MMP) in QBC939 cells.
RT-qPCR. QBC939 cells in the mid-log phase were seeded in 6-well plates (3x10 5 cells/well in 2 ml RPMI 1640 medium) and cultured overnight at 37˚C. Cells were allowed to culture to 70% confluence and were treated with 0, 2, 4, 6, 8 and 10 µM solamargine for 24 h at 37˚C. The treated cells were washed with PBS twice and total RNA in cells was extracted using the TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). According to the manufacturer's protocol of the first cDNA synthesis kit for RT-qPCR, mRNA was reverse transcribed to cDNA by using the reaction system (Reaction Mix 4 µl, Maxima Enzyme Mix 2 µl, Template RNA 500 ng, and add nuclease-free Water to 20 µl) and the reaction procedure (25˚C for 10 min, 50˚C for 15 min, 85˚C for 5 min). The reaction system included (Maxima SYBR Green/ROX qPCR Master Mix (Thermo Fisher Scientific, Inc.) 10 µl, forward primer 0.3 µM, reverse primer 0.3 µM, Template DNA 300 ng, and nuclease-free water until a final volume of 25 µl), the thermocycling conditions were 95˚C for 10 min, 1 cycle; 95˚C for 15 sec, 60˚C for 30 sec and 72˚C for 30 sec, 40 cycles of qPCR, the genes (Bax, Bcl-2, Bcl-xL, XIAP) mRNA relative expression were detected by fluorescence quantitative PCR equipment (Applied Biosystems, Thermo Fisher Scientific, Inc.) and analyzed by the 2 -∆∆Cq method. GAPDH mRNA expression was used as the control. Primers used in the experiments were synthesized by GenScript Biotech (Nanjing, China) and are listed in Table I .
Western blot. QBC939 cells in the period of logarithmic phase were seeded in 6-well plates (3x10 5 cells/well in 2 ml RPMI 1640 medium) and cultured overnight at 37˚C in an atmosphere containing 5% CO 2 . Cells were allowed to culture to 70% confluence/well and were treated with solamargine at the indicated concentration (0, 2, 4, 6, 8 and 10 µM) for 24 h at 37˚C. Cells were washed with ice cold PBS three times and digested using RIPA lysis buffer with protease phosphatase inhibitor cocktail (Thermo Scientific, Inc., Waltham, MA, USA) on ice for 5 min. Cell lysates were selected and centrifuged (12,000 x g, 10 min, 4˚C) to remove the cell debris. Total protein concentration was determined using the BCA Protein Assay kit (Beyotime Institute of Biotechnology) and detected using the Multiskan Spectrum Microplate Reader. Cell lysates are mixed with 2X Sample Buffer and heated in water at 100˚C for 5 min. Prepared protein (~30 µg per lane) was separated using SDS-PAGE (12% gels) and transferred onto polyvinylidene difluoride membranes (Merck KGaA). After the proteins were transferred to the PVDF membrane, protein was blocked using Tris-Buffered Saline (TBS) containing 5% non-fat milk for 1 h at room temperature and incubated with primary antibody (Bax, Bcl-2, caspase3, caspase7, XIAP, PARP and β-actin, all antibodies come from Cell Signaling Technology Incorporation, antibodies were diluted by 1:1,000) overnight at 4˚C. The PVDF membrane was washed with TBS-0.1% Tween 20 and incubated with the Dylight 800-labeled goat anti-rabbit immunoglobulin G (H+L) fluorescence antibody (dilution, 1:10,000; catalog no. 072-07-15-06, KPL, Inc., Gaithersburg, MD, USA) for 1 h at room temperature. The blot membrane was exposed and scanned by the Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE, USA).
Statistical analysis. Data are expressed as the mean ± standard deviation of 3 independent experiments. The difference between different groups was analyzed using a one-way analysis of variance (with Tukey's post-hoc test) or a Student's t-test. P<0.05 was considered to indicate a statistically significant difference. The data were analyzed using SPSS software (version 16.0; SPSS, Inc., Chicago, IL, USA) and graphs were plotted using GraphPad Prism software (version 5; GraphPad Software, Inc., La Jolla, CA, USA). Table I . Primers used for quantitative polymerase chain reaction.
Results
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Bcl-2, B-cell lymphoma-2; xL, extra large; Bax, Bcl-2-associated X protein; XIAP, X-linked inhibitor of apoptosis protein. precision of experiment and the quality of solamargine, HPLC was used to determine the purity of solamargine. The results revealed that the purity of solamargine was >98% (Fig. 1B) . The effect of solamargine on QBC939 cells was observed using light microscopy (magnification, x200) at first. As the concentration of solamargine increased (0, 2, 4, 6, 8 and 10 µM), the morphology of cholangiocarcinoma cells changed markedly at 24 h. Solamargine may cause shrinkage, irregularity and inhibit the viability of cells (Fig. 2A) . The viability of human cholangiocarcinoma QBC939 cells was analyzed using an MTT assay after 24 h treatment with solamargine (0, 2, 4, 6, 8, 10, 12 µM). Solamargine treatment significantly inhibited the viability of QBC939 cells in dose-dependent manner (concentration, >4 µM; Fig. 2B ). The half-maximal (Fig. 3) .
Solamargine alters the mitochondrial membrane potential in QBC939 cells. The present study identified that solamargine may induce the pro-apoptosis of human cholangiocarcinoma cells significantly. The alteration in mitochondrial membrane potential may lead to early apoptosis (14) . Therefore, in the present study, QBC939 cells were treated with different concentrations of solamargine (0, 2, 4, 6, 8 and 10 µM) for 24 h and stained with JC-1 staining buffer for 20 min in the dark. Subsequently, the MMP of QBC939 cells was determined using flow cytometry. As presented in Fig. 4A , compared with the untreated group, the results demonstrated an increase in green fluorescence and a decrease in red fluorescence, which indicated that solamargine caused a depolarized MMP in QBC939 cells (Fig. 4B) .
Solamargine alters the expression and activation of apoptosis-associated proteins in QBC939 cells. Based on the above results, the molecular mechanism of apoptosis effect of solamargine on human cholangiocarcinoma QBC939 cells was subsequently investigated. The present study assessed the expression of apoptosis-associated proteins in QBC939 cells, after 24 h treatment with different concentrations of solamargine (0, 2, 4, 6, 8 and 10 µM), using RT-qPCR and western blot analysis. The total RNA of QBC939 cells was extracted using TRIzol reagent and the mRNA was transcribed into cDNA. The relative expression of Bax, Bcl-2, Bcl-extra-large (Bcl-xL) and XIAP mRNA was determined using RT-qPCR (using GAPDH as the reference gene). The results revealed that solamargine significantly inhibited Bcl-2 and XIAP mRNA levels but significantly increased the mRNA level of Bax (Fig. 5A) . The total protein of QBC939 cells was extracted using RIPA cell lysis buffer, after 24 h incubation, and quantitated using the BCA protein assay kit. The protein levels of Bax, Bcl-2, caspase 3, cleaved-caspase 3, caspase 7, XIAP, PARP and cleaved PARP were determined using western blot analysis. As presented in Fig. 5B , solamargine increased the protein expression of Bax, caspase 3, cleaved-caspase 3, caspase 7 and cleaved PARP, but decreased the protein expression of Bcl-2, XIAP and PARP. Therefore, solamargine may influence apoptosis-associated proteins to inhibit the viability of QBC939 cells.
Discussion
Cholangiocarcinoma is a type of aggressive and refractory malignancy, and characterized by late diagnosis and poor outcomes; therefore, identifying novel therapeutic drugs is required (2, 17) . Solamargine, a type of alkaloid derived from S. nigrum, may inhibit the proliferation of and induce apoptosis in multiple types of tumor cell lines (including human breast cancer, lung cancer and hepatocellular carcinoma cell lines) (7) (8) (9) (10) (11) (12) (13) . The present study explored the therapeutic effect of solamargine on human cholangiocarcinoma QBC939 cells preliminarily. The present study revealed that alkaloid solamargine treatment on QBC939 cells can result in the emergence of cell shrinkage, irregularity and apoptotic bodies, which were observed by using a light microscope. An MTT assay revealed that solamargine inhibited the cell viability of QBC939 cells in the dose-dependent manner and the value of IC 50 was 9.81 µM. The results of the present study suggested that solamargine may be a chemotherapeutic drug for the treatment of human cholangiocarcinoma. Therefore, future studies may focus on exploring how solamargine inhibits the viability of QBC939 cells. Apoptosis is a type of programmed cell death and could serve as an important antitumor target (15, 18) . Induction of apoptosis in the tumor microenvironment may inhibit excessive cell proliferation and is an effective therapeutic strategy against cancer (19) . The present study demonstrated that solamargine induced apoptosis of QBC939 cells significantly in a dose-dependent manner, as determined using flow cytometry. A previous study revealed that the alteration in MMP is an early event of pro-apoptosis and may result in the release of cytochrome c in mitochondria, which may induce the activation of caspase 9 (14) . The alterations in MMP induced by solamargine, determined using flow cytometry in the present study, demonstrated that solamargine could change MMP in QBC939 cells. Apoptosis is associated with multiple pro-apoptotic proteins (including Bax and caspase 3) and anti-apoptotic proteins (including Bcl-2 and XIAP) and is determined by the ratio of pro-to anti-apoptotic proteins (20) . To evaluate the underlying molecular mechanism of solamargine-induced apoptosis, the alterations in apoptosis-associated gene and protein expression were detected using RT-qPCR and western blot analysis. The results indicated that solamargine increased the expression of Bax, caspase 3, cleaved caspase 3, caspase 7 and cleaved PARP and decreased the expression of Bcl-2, Bcl-xL, XIAP and PARP. Therefore, solamargine may be an effective chemotherapeutic agent against cholangiocarcinoma by inducing apoptosis.
The results of the present study indicated that solamargine may induce apoptosis significantly in human cholangiocarcinoma QBC939 cells via the MMP pathway. Solamargine is the one member of natural compounds (luteolin, matrine, berberine and so on) against human cholangiocarcinoma (21, 22) , and the results of the present study suggested that solamargine may be an effective drug candidate against cholangiocarcinoma. Since the present study only included in vivo experiments, additional in vitro assays are required to validate whether solamargine may be a therapeutic agent for the treatment of cholangiocarcinoma. were analyzed by WC and XW. FZ and ZY were the major contributors to study design and wrote the manuscript. All authors read and approved the final manuscript.
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